hydroxyurea

P=N/A, N=1600, Recruiting, Duke University | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Sep 2024 --> Jul 2026

P4, N=96, Recruiting, Bahria University | Active, not recruiting --> Recruiting

This work created a 12-gene signature based on NM, preliminary investigated immune infiltration in two risk categories, and discovered some possible anti-tumor medications. To sum up, our study findings offer fresh perspectives on the roles played by NM-associated genes in HCC development, prognosis, immunological response, and medication screening.

P2, N=27, Recruiting, Xiamen Amoytop Biotech Co., Ltd. | Not yet recruiting --> Recruiting

Linked to these disputes is another: whether therapy with hydroxyurea promotes acute leukemia in disorders with a substantial possibility of longevity...Most of these changes, however, conflicted with prior well-validated, phenotypically driven diagnostic criteria and the management of these disorders. The aim of this review is to examine these conflicts and demonstrate how genomic discoveries in myeloproliferative neoplasms can be used to effectively complement the known phenotypic features of these disorders for their diagnosis and management.

P3, N=300, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: May 2029 --> Apr 2027

P4, N=96, Active, not recruiting, Bahria University | Not yet recruiting --> Active, not recruiting

P=N/A, N=40, Recruiting, Ann & Robert H Lurie Children's Hospital of Chicago | Trial completion date: Jun 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

P=N/A, N=68, Active, not recruiting, Ann & Robert H Lurie Children's Hospital of Chicago | Trial primary completion date: Nov 2023 --> Dec 2024

Ruxolitinib is a Janus kinase inhibitor that can alleviate pruritus and decrease splenomegaly in patients who are intolerant of or resistant to hydroxyurea. To decrease the risk of thrombosis, all patients with PV should be treated with aspirin and therapeutic phlebotomy to maintain a hematocrit of less than 45%. Cytoreductive therapies, such as hydroxyurea or interferon, are recommended for patients at high risk of thrombosis.

P3, N=586, Recruiting, University of Birmingham | Trial completion date: Feb 2028 --> Apr 2030 | Trial primary completion date: Aug 2026 --> Oct 2028

P3, N=315, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

P3, N=300, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of

Management included observation in 6 (46.3%), hydroxyurea in 3 (23.1%), imatinib in 3 (23.1%) and Interferon-α (IFN-α) in 1 (7.7%) patients. Effective management of newly diagnosed CML-CP during pregnancy is contingent on the trimester of presentation. Further research and collaboration are warranted to develop standardised guidelines for managing pregnancy-associated CML, particularly in LMICs.

P2, N=46, Recruiting, Forma Therapeutics, Inc. | Trial completion date: Oct 2026 --> May 2026

P1/2, N=33, Completed, Nova Laboratories Limited | Phase classification: P2 --> P1/2

P2, N=117, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

Antiplatelet therapy was started with acetylsalicylic acid 100 mg and clopidogrel 75 mg once a day. With the recommendation of hematology, cytoreductive treatment, hydroxyurea 1000 mg twice a day, was started. The patient's complaints were resolved at the end of the second day, and the patient with minimal ataxia was discharged with recommendations. Patients with ET should be aware of ischemic cerebrovascular disease and consider antiplatelet and cytoreductive treatment options.

P2, N=76, Completed, University of Chicago | Active, not recruiting --> Completed

First, a rat model of RSA was established using hydroxyurea in combination with mifepristone. It was elucidated that all three were involved in the regulation of progesterone levels and immune function. It initially revealed the mechanism of action of YP in enhancing the improvement of RSA, and it provided a theoretical basis for the quality assessment of YP.

The use of combination therapies, such as hydroxyurea alongside diltiazem, suggests more efficient and effective MG management compared to monotherapy. Since the efficacy of traditional therapies is limited in most cases due to resistance mechanisms in CSCs, further studies on the biology of CSCs are warranted to develop therapeutic interventions that are likely to be effective in MG. Consequently, improved diagnostic approaches may lead to personalised treatment plans tailored to the specific needs of each patient.

P2, N=62, Completed, University of Chicago | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2024 | Trial primary completion date: Mar 2019 --> Sep 2024

P4, N=96, Not yet recruiting, Bahria University

P2, N=64, Completed, Vanderbilt University Medical Center | Active, not recruiting --> Completed | Trial completion date: Jan 2027 --> Nov 2023

P2, N=46, Recruiting, Forma Therapeutics, Inc. | Trial completion date: Feb 2026 --> Oct 2026 | Trial primary completion date: Jan 2025 --> Jul 2025

P2, N=27, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology

P2, N=76, Active, not recruiting, University of Chicago | Trial completion date: Jul 2025 --> Sep 2024 | Trial primary completion date: Jul 2025 --> Sep 2024

All cases were successfully managed with hydroxyurea...In conclusion, APL patients undergoing ATRA-ATO therapy with lower fibrinogen levels and platelet counts at diagnosis and with a massive bone marrow blast infiltrate should be carefully monitored for the development of leucocytosis during induction. DS and other treatment-related complications seem to occur almost exclusively in patients developing leucocytosis, who should necessarily receive DS prophylaxis and more intensive monitoring and supportive therapy to prevent treatment complications.

Treatment with phlebotomy, hydroxyurea, and aspirin resulted in significant improvements in ocular symptoms and hematological parameters within 60 days. CONCLUSIONS This case underscores the critical role of primary care in the early detection of polycythemia vera. Timely identification and appropriate referral from primary care settings are essential to avoid diagnostic delays and ensure effective management, improving patient outcomes and preventing complications.

P=N/A, N=241, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

P4, N=220, Recruiting, Vanderbilt University Medical Center | Not yet recruiting --> Recruiting

P3, N=320, Recruiting, Geron Corporation | Trial completion date: Apr 2027 --> Nov 2026 | Trial primary completion date: Apr 2027 --> Nov 2026

We conclude that short-term HU treatment entails differentiation of erythroid progenitor cells and alters the characteristics of LSC in CML. The results imply that studies of LSC and progenitor populations in CML should take effects of initial HU therapy into account.

P2, N=40, Suspended, St. Jude Children's Research Hospital | Trial completion date: Jul 2025 --> Aug 2027 | Trial primary completion date: Jul 2024 --> Aug 2026

To our best knowledge, the present case is the first one with JAK2 mutation preceding the acquisition of t(8;21). Our result suggests that t(8;21); RUNX1::RUNX1T1 can be generated as a late event in the progression of JAK2-mutated myeloproliferative neoplasms. The case presented typical morphological and immunophenotypic features associated with t(8;21) acute myeloid leukemia.

P2, N=36, Recruiting, University of Chicago | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025

P2, N=27, Not yet recruiting, Xiamen Amoytop Biotech Co., Ltd.

Hydroxyurea, gemcitabine and triapine all increased cell size, SSTR2A expression, and [177Lu]Lu-DOTA-TATE uptake, whilst reducing cell metabolic viability in U2OS + SSTR2A cells when compared to [177Lu]Lu-DOTA-TATE monotherapy. Further investigations could transform patient care and positively increase outcomes for patients treated with [177Lu]Lu-DOTA-TATE.

The treatment landscape of polycythemia vera (PV) has seen major advancements within the last decade including approval of ruxolitinib in the second line setting after hydroxyurea, ropegylated interferon-α2b, and advanced clinical development of a novel class of agents called hepcidin mimetics...The discovery of hepcidin mimetics has come as a breakthrough in restoring iron homeostasis, achieving phlebotomy-independence and may lead to improved thrombosis-free survival with stricter hematocrit control. On the other hand, emerging data with IFN- α and ruxolitinib as well as combination of the two agents suggests the potential for achieving molecular remission in a subset of PV patients and long-term follow-up is awaited to validate the correlation of molecular responses with clinically relevant outcomes of progression-free and thrombosis-free survival.

Four tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, bosutinib, and nilotinib, are approved by the United States Food and Drug Administration (FDA) for first-line treatment of newly diagnosed CML in the chronic phase (CML-CP)...Patients who develop the T315I "gatekeeper" mutation display resistance to all currently available TKIs except ponatinib, asciminib, and olverembatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML-CP and failure (due to resistance) of at least two TKIs and for all patients in advanced-phase disease. Older patients who have a cytogenetic relapse post-failure on all TKIs can maintain long-term survival if they continue a daily most effective/least toxic TKI, with or without the addition of non-TKI anti-CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, and others).

P1, N=48, Completed, University of Chicago | Active, not recruiting --> Completed | Trial completion date: Nov 2027 --> Jan 2024 | Trial primary completion date: Nov 2027 --> Jan 2024

P4, N=220, Not yet recruiting, Vanderbilt University Medical Center